Approximately 70–80% of patients with bladder cancer initially present with a non-muscle-invasive disease (NMIBC). In these patients, transurethral resection (TURBT) with or without adjuvant intravesical chemo- or immunotherapy gives a chance for cure. However, for stage T1 or high-grade (HG) tumors, there is a considerable risk of residual disease and/or understating after initial TURBT. Hence from the above literature findings the present study was planned to assess the clinical value and safety of reTURBT in different clinical indications. The total 25 patients were included in the study from Indira Gandhi Institute of Medical Sciences, Patna. The enrolled patients were having proven histological diagnosis of nonmuscle invasive urothelial cancer with either high grade or T1 cancers on histopathology were enrolled. ReTURBT is a safe procedure that improves the staging of bladder cancer and increases the chances for complete cancer ablation. It should be considered in all patients with stages T1, Tx, or high-grade bladder cancer.